𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evaluation of acupuncture in the treatment of Parkinson's disease: A double-blind pilot study

✍ Scribed by Adrian Cristian; Meredith Katz; Eileen Cutrone; Ruth H. Walker


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
60 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

As many as 40% of patients with Parkinson's disease (PD) use some form of complementary medicine during the course of their illness, and many try acupuncture. One nonblinded study of the effects of acupuncture in PD suggested that it might be helpful for some aspects of PD. We performed a double‐blind, randomized, pilot study comparing acupuncture to a control nonacupuncture procedure to determine the effects of acupuncture upon a variety of PD‐associated symptoms. Fourteen patients with Stage II or III PD received acupuncture or a control nonacupuncture protocol. Before and after treatment, patients were evaluated using the Motor subscale of the Unified Parkinson's Disease Rating Scale (UPDRS), the Parkinson's Disease Questionnaire (PDQ‐39), and the Geriatric Depression Scale. There were no statistically significant changes for the outcomes measured. In the patients who received acupuncture, nonsignificant trends toward improvement were noted in the Activities of Daily Living score of the PDQ‐39, the PDQ‐39 Summary Index, and the Motor subscale of the UPDRS. Β© 2005 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Randomized, double-blind, pilot evaluati
✍ Robert A. Hauser; Kelly E. Lyons; Terry McClain; Summer Carter; David Perlmutter πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 80 KB

## Abstract The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of intravenous glutathione in Parkinson's disease (PD) patients. This was a randomized, placebo‐controlled, double‐blind, pilot trial in subjects with PD whose motor symptoms were not adequate

Double-blind study of pardoprunox, a new
✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o

Excess burden of constipation in Parkins
✍ Julie Kaye; Heather Gage; Alan Kimber; Lesley Storey; Patrick Trend πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 1 views

An analysis was undertaken of clinic-based questionnaires that asked people with Parkinson's disease and a control group of older people without a known neurological condition about their experiences of constipation. People with Parkinson's disease report higher constipation on a validated objective

Comparison of desipramine and citalopram
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Atomoxetine for the treatment of executi
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 321 KB πŸ‘ 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi